ChromaDex Corporation (CDXC)
| Market Cap | 868.91M |
| Revenue (ttm) | 56.90M |
| Net Income (ttm) | -22.68M |
| Shares Out | 61.70M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $13.93 |
| Previous Close | $18.74 |
| Change ($) | -4.81 |
| Change (%) | -25.67% |
| Day's Open | 20.24 |
| Day's Range | 13.76 - 20.54 |
| Day's Volume | 28,499,207 |
| 52-Week Range | 2.50 - 23.66 |
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Mo...
ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor. The company will sell...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its finan...
ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment ...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in ...
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investi...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available o...
Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 36.36% and -0.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales o...
On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its fin...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at ...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Cell...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recov...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will...
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further high...
ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #AutismResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigatin...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global Chro...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibi...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Alle...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential...
ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 18.18% and 4.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed cli...
ChromaDex Corp. (CDXC) CEO Rob Fried on Q4 2019 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 8.33% and 2.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (NASDAQ:CDXC) reported Q4 results. Quarterly Results • Earnings came in at a loss of $0.11 per share, in line with the estimate.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models Preclinical study demonstrates the effects of sh...
Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service
ChromaDex launches new research tools for the CBD industry with line of reference standards ChromaDex launches new research tools for the CBD industry with line of reference standards
ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity ChromaDex receives authoriza...
Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 Study expands on recent...
LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook® , a leading publication for the nutraceuticals industry, recently awa...
Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners
About CDXC
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets an... [Read more...]
| Industry Biotechnology | |
| CEO Robert Fried | Employees 110 |
| Stock Exchange NASDAQ | Ticker Symbol CDXC |
Financial Performance
In 2019, ChromaDex's revenue was $46.29 million, an increase of 46.69% compared to the previous year's $31.56 million. Losses were -$32.15 million, -3.51% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 7.90, which is a decrease of -43.29% from the latest price.